Evidence map›Paper›PMID 32711577›Full record

ArticleBMC research notes2020

The effects of intravitreal adalimumab injection on pseudophakic macular edema.

Mohsen Farvardin, Ehsan Namvar, Fatemeh Sanie-Jahromi, Mohammad Karim Johari

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC research notes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mohsen FarvardinPoostchi Ophthalmology Research Center, Department of Poostchi Ophthalmology, Shiraz University of Medical Sciences, Zand Street, Shiraz, Fars, Iran.
Ehsan NamvarPoostchi Ophthalmology Research Center, Department of Poostchi Ophthalmology, Shiraz University of Medical Sciences, Zand Street, Shiraz, Fars, Iran. namvar.e@gmail.com.
Fatemeh Sanie-JahromiPoostchi Ophthalmology Research Center, Department of Poostchi Ophthalmology, Shiraz University of Medical Sciences, Zand Street, Shiraz, Fars, Iran.
Mohammad Karim JohariPoostchi Ophthalmology Research Center, Department of Poostchi Ophthalmology, Shiraz University of Medical Sciences, Zand Street, Shiraz, Fars, Iran.
Shiraz University of Medical Sciences · IR

Funding

Shiraz University of Medical Sciences Grant# 6327
6 · The paper itself

Abstract

objectivePseudophakic macular edema is a frequent complication following cataract surgery. Inflammation is a major etiologic factor in the development of pseudophakic cystoid macular edema. Tumor necrosis factor-alpha has an important role in ocular inflammation. Adalimumab (Humira) is an inhibitor of tumor necrosis factor-alpha that has been approved in the United States. An open-label, uncontrolled, prospective, interventional study of five consecutive patients (5 eyes) with cystoid macular edema who were treated with off-label intravitreal adalimumab at Khalili Hospital was conducted. Slit-lamp examination and optical coherence tomography were done for all patients.

resultsNo statistically significant difference was detected between best corrected visual acuity and central macular thickness before and after injection in pseudophakic macular edema. One patient developed uveitis approximately 2 weeks after injection. Based on the results, adalimumab does not appear to be an effective treatment for pseudophakic macular edema, and it may cause uveitis. Caution should be exercised when using this drug. Trial registration Iranian Registry of Clinical Trials IRCT2016100430130N1, 2016.12.03, Retrospectively registered.

Indexed as

Macular EdemaAdalimumabAntibodies, Monoclonal, HumanizedGlucocorticoidsHumansIntravitreal InjectionsIranProspective StudiesTomography, Optical CoherenceTreatment OutcomeVisual AcuityAdalimumabAntibodies, Monoclonal, HumanizedGlucocorticoidsAdalimumabIntravitreal injectionPseudophakic macular edema

Identifiers

PMID32711577
PMCPMC7382825
OpenAlexW3044258692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.